Moreover, the fact that AR and CDC6-mediated DNA replication play a role in prostate cancers and their interaction alters the development of CRPC raises the potential for the utility of Remodelin in targeting DNA replication as a therapeutic approach in the treatment of prostate cancers. The gene discussed is CDC6; the disease is Familial prostate cancer.